Immunome, Inc. (IMNM)
Free
No email, no account, no signup.
Pulling latest news for Immunome, Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Targeted oncology and antibody therapeutics
Market Cap
$2.6B
Market sentiment
Sentiment has deteriorated materially as the stock broke to 52-week lows after ASCO, suggesting the market either “sold the news” or is reassessing probability/timing of regulatory outcomes and commercial potential despite supportive analyst commentary.
Why NEUTRAL ?
ASCO is now in the price and the market reaction has been negative on elevated volume, increasing the risk of continued volatility and weak technicals. However, the core upside remains tied to regulatory milestones (FDA filing acceptance/review timeline and later decision), so the appropriate stance remains to review/resize exposure rather than aggressively averaging down or adding ahead of clearer signals.
- Maintain a core position if already owned, but avoid aggressive adds ahead of FDA acceptance/ASCO; consider scaling exposure around catalysts based on risk budget.
We're already tracking Immunome, Inc. — here are the latest events we've registered
Recent News
- Since 2026-06-03, Immunome has not released new clinical/regulatory updates or financing events. On June 4, 2026, the company reported inducement grants (353,000 options to 20 new hires, $20.78 strike, 4-year vesting). The stock remained weak into early June post-ASCO, with no clear new company-specific triggers.
Want to know how this news affects Immunome, Inc.? Order the analysis.
Order analysis – Catalysts
FDA: NDA acceptance (varegacestat)
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Immunome, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.